Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy

Miyakubo, Tomoko; Mukai, Ryo; Matsumoto, Hidetaka; Morimoto, Masahiro; Takahashi, Maki; Nagai, Kazuki; Nakamura, Kosuke; Hoshino, Junki; Akiyama, Hideo

doi:10.2147/opth.s386222

Cited by 3 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ranibizumab showed a complete regression rate of 25% 12 , while in our previous study, aflibercept administered once every 2 months showed a rate of 50% 13 , 14 . Brolucizumab showed a rate of 79–90% 15 , 16 , and photodynamic therapy showed a rate of over 70% 17 , 18 . Our findings demonstrated a noteworthy 50% rate of complete regression following 1 year of faricimab treatment for PCV.…”

Section: Discussionmentioning

confidence: 99%

One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan

Mukai,

Kataoka,

Tanaka

et al. 2024

Sci Rep

Self Cite

View full text Add to dashboard Cite

This multicentre retrospective study evaluated the 1-year outcomes and safety profile of faricimab in treatment-naïve patients with neovascular age-related macular degeneration (nAMD). Fifty-five patients (57 eyes) underwent loading therapy comprising three monthly faricimab injections. If dryness was achieved by the third month, subsequent treat-and-extend (TAE) follow-up continued at a minimum 8-week interval thereafter. If wet macula persisted at the third month, a fourth dose was administered, followed by the TAE regimen. After 1 year, improvements in visual acuity (0.44 ± 0.46 [baseline] to 0.34 ± 0.48; p < 0.01) and central foveal thickness (326 ± 149 [baseline] to 195 ± 82 μm; p < 0.0001) were significant. Dry macula, characterised by the absence of intraretinal or subretinal fluid, was achieved in 65% of cases. Treatment intervals varied, ranging from 8 to 16 weeks, with 44% of eyes extending to a 16-week interval, followed by 33% at 8 weeks, 16% at 12 weeks, 5% at 14 weeks, and 2% at 10 weeks. Notably, 50% of the polypoidal choroidal vasculopathy patients exhibited complete regression of polypoidal lesions between 12 and 15 months. Faricimab treatment in nAMD patients induced significant improvements in central vision and retinal morphology. Two cases of retinal pigment epithelial tears and one case of iritis were reported as ocular complications.

show abstract

Section: Discussionmentioning

confidence: 99%

One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan

Mukai,

Kataoka,

Tanaka

et al. 2024

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…There was little information on the incidence of atrophy after PDT for PNV. As for PCV, Miyakubo et al mentioned that the frequencies of macular atrophy expansion in combination therapy during 2 years was 33% with no significant difference compared to anti-VEGF monotherapy (26%) [ 28 ]. However, Miyata et al reported that 5-year incidence of macular atrophy was greater in initial combined PDT than in anti-VEGF monotherapy [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

Intravitreal anti-vascular endothelial growth factor and combined photodynamic therapy for pachychoroid neovasculopathy: long-term treatment outcomes

Tanaka,

Azuma,

Aoki

et al. 2024

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Purpose To examine the long-term visual outcomes after initial treatment with combined photodynamic therapy (PDT) or aflibercept treat-and-extend (TAE) monotherapy in patients with pachychoroid neovasculopathy (PNV). Methods Patients diagnosed with PNV, initially treated with PDT combined with anti-vascular endothelial growth factor (VEGF) or intravitreal aflibercept (IVA) monotherapy in the TAE protocol and followed up for at least 6 months, were included in the study. Medical records were retrospectively reviewed. Survival analysis was performed, in which deterioration in logMAR visual acuity by 0.1 or 0.3 is defined as “death.” The annual number of treatments was also analyzed. Sub-analysis was performed on 33 patients diagnosed with PNV without polypoidal lesions. Results This study included 46 patients (23 in the initial combined PDT group and 23 in the IVA TAE group). Mean age, sex, mean baseline logMAR visual acuity, or duration of observation (3.6 ± 3.2 years vs. 3.1 ± 1.9 years) in both groups were comparable. As for visual outcome, no significant differences were found in survival analysis based on worsening of 0.1 or 0.3 logMAR (3-year survival; 26% vs. 26%, 91% vs. 90%, respectively). Meanwhile, the additional number of anti-VEGF injections per year was significantly lower in the initial combined PDT group than in the IVA TAE group (1.0 ± 1.3 vs. 4.1 ± 1.5, p < 0.0001). No significant differences were found in the number of additional PDTs per year (0.07 ± 0.20 vs. 0.02 ± 0.09, p = 0.27). Similar results were found in a sub-analysis of 33 patients without polyps. Conclusion In the treatment of PNV, regardless of the presence of polyps, the long-term visual outcomes were similar between the initial combined PDT and IVA TAE monotherapy. However, the annual number of anti-VEGF injections was lower in the initial combined PDT group than in the aflibercept TAE group, whereas that of PDT was comparable.

show abstract

Three-year outcome of photodynamic therapy combined with VEGF inhibitor for pachychoroid neovasculopathy

Nomura,

Aoki,

Kitamoto

et al. 2024

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy

Cited by 3 publications

References 25 publications

One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan

One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan

Intravitreal anti-vascular endothelial growth factor and combined photodynamic therapy for pachychoroid neovasculopathy: long-term treatment outcomes

Three-year outcome of photodynamic therapy combined with VEGF inhibitor for pachychoroid neovasculopathy

Contact Info

Product

Resources

About